Product Code: ETC9953238 | Publication Date: Sep 2024 | Updated Date: Aug 2025 | Product Type: Market Research Report | |
Publisher: 6Wresearch | No. of Pages: 75 | No. of Figures: 35 | No. of Tables: 20 | |
1 Executive Summary |
2 Introduction |
2.1 Key Highlights of the Report |
2.2 Report Description |
2.3 Market Scope & Segmentation |
2.4 Research Methodology |
2.5 Assumptions |
3 United Kingdom (UK) RNA Therapy Clinical Trials Market Overview |
3.1 United Kingdom (UK) Country Macro Economic Indicators |
3.2 United Kingdom (UK) RNA Therapy Clinical Trials Market Revenues & Volume, 2021 & 2031F |
3.3 United Kingdom (UK) RNA Therapy Clinical Trials Market - Industry Life Cycle |
3.4 United Kingdom (UK) RNA Therapy Clinical Trials Market - Porter's Five Forces |
3.5 United Kingdom (UK) RNA Therapy Clinical Trials Market Revenues & Volume Share, By Modality, 2021 & 2031F |
4 United Kingdom (UK) RNA Therapy Clinical Trials Market Dynamics |
4.1 Impact Analysis |
4.2 Market Drivers |
4.2.1 Increasing prevalence of genetic disorders in the UK, driving the demand for RNA therapy clinical trials. |
4.2.2 Growing investments in healthcare research and development in the UK. |
4.2.3 Favorable government regulations and initiatives supporting RNA therapy clinical trials in the UK. |
4.3 Market Restraints |
4.3.1 High costs associated with RNA therapy clinical trials, limiting accessibility. |
4.3.2 Regulatory challenges and approval processes for RNA therapies in the UK. |
5 United Kingdom (UK) RNA Therapy Clinical Trials Market Trends |
6 United Kingdom (UK) RNA Therapy Clinical Trials Market, By Types |
6.1 United Kingdom (UK) RNA Therapy Clinical Trials Market, By Modality |
6.1.1 Overview and Analysis |
6.1.2 United Kingdom (UK) RNA Therapy Clinical Trials Market Revenues & Volume, By Modality, 2021- 2031F |
6.1.3 United Kingdom (UK) RNA Therapy Clinical Trials Market Revenues & Volume, By RNA Interference, 2021- 2031F |
6.1.4 United Kingdom (UK) RNA Therapy Clinical Trials Market Revenues & Volume, By Antisense Therapy, 2021- 2031F |
6.1.5 United Kingdom (UK) RNA Therapy Clinical Trials Market Revenues & Volume, By Messenger RNA, 2021- 2031F |
6.1.6 United Kingdom (UK) RNA Therapy Clinical Trials Market Revenues & Volume, By Oligonucleotide, 2021- 2031F |
7 United Kingdom (UK) RNA Therapy Clinical Trials Market Import-Export Trade Statistics |
7.1 United Kingdom (UK) RNA Therapy Clinical Trials Market Export to Major Countries |
7.2 United Kingdom (UK) RNA Therapy Clinical Trials Market Imports from Major Countries |
8 United Kingdom (UK) RNA Therapy Clinical Trials Market Key Performance Indicators |
8.1 Patient recruitment rate for RNA therapy clinical trials in the UK. |
8.2 Success rate of RNA therapy clinical trials in the UK. |
8.3 Time to market for RNA therapy products developed through clinical trials in the UK. |
9 United Kingdom (UK) RNA Therapy Clinical Trials Market - Opportunity Assessment |
9.1 United Kingdom (UK) RNA Therapy Clinical Trials Market Opportunity Assessment, By Modality, 2021 & 2031F |
10 United Kingdom (UK) RNA Therapy Clinical Trials Market - Competitive Landscape |
10.1 United Kingdom (UK) RNA Therapy Clinical Trials Market Revenue Share, By Companies, 2024 |
10.2 United Kingdom (UK) RNA Therapy Clinical Trials Market Competitive Benchmarking, By Operating and Technical Parameters |
11 Company Profiles |
12 Recommendations |
13 Disclaimer |